Navigation Links
Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:12/2/2009

FRAZER, Pa., Dec. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year period of marketing exclusivity for NUVIGIL that extends until June 15, 2010. In addition, including the six-month pediatric extension, the '516 Patent, the '346 Patent, and the '570 Patent expire on April 6, 2015, May 29, 2024, and June 18, 2024, respectively. Teva did not challenge Orange Book-listed U.S. Patent No. 4,927,855 (the "'855 Patent"), which provides additional protection until October 22, 2010, the expiration date of the '855 Patent.

The lawsuit is based upon an Abbreviated New Drug Application (ANDA) filed by Teva seeking FDA approval for a generic equivalent of armodafinil to be sold in the United States. Teva alleges that the above NUVIGIL patents are invalid, unenforceable and/or will not be infringed by Teva's manufacture, use or sale of the product described in its ANDA.

"We believe that our NUVIGIL patents, approved by the US Patent & Trademark Office, are valid, enforceable and are infringed by the proposed Teva ANDA product ," said Jerry Pappert, Executive Vice President and General Counsel. "Our patent position for this product is strong and we intend to vigorously defend our intellectual property."

The filing of this lawsuit is provided for by the Hatch-Waxman Act, a federal statute governing certain aspects of generic drug approvals. Under that statute, the filing of the lawsuit stays any FDA approval of the Teva ANDA until the earlier of entry of a district
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
2. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
3. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
4. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
5. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
6. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Nuclear medicine market is estimated to ... Nuclear are drugs that contain radionuclide-emitting ionization radiation, ... and treat diseases. Increasing incidences of ... and ready availability of radiopharmaceuticals are the major ... awareness and use of SPECT and PET also ...
(Date:9/23/2014)...  SI-BONE, Inc., a medical device company that pioneered ... a minimally invasive surgical (MIS) device indicated for fusion ... U.S. Patent and Trademark Office has awarded the company ... fixation and fusion of bone.  This newly issued patent ... may be placed from one bone across a joint ...
(Date:9/23/2014)... , Sept. 23, 2014   LabStyle Innovations ... Diabetes Management Solution, today announced that it has ... of shares of preferred stock and warrants.  No ... estimated offering expenses, LabStyle expects to secure net ... LabStyle intends to use the ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5
... Use of,a low profile PressureWire yields a ... to catheter-derived pressure gradient,(CPG) measurements, according to a ... Vol. 20, Issue 1: 63-65)., The authors ... a,catheter and PressureWire correlated with anatomic stenosis, PressureWire,gradient ...
... 27 Puroast(R) Low Acid Coffee,has conducted both ... its great tasting, gourmet coffee provides symptom relief ... brew. Puroast(R) achieves,this without extractions, substitutes or additives; ... full-bodied taste., Prior chemistry research at University ...
Cached Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Low Acid Coffee Backed By Scientific Research 2
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT CADDY is patient ... "Call lights are often found on the floor, lost in ... out of the patient's reach. In order to make sure ... it, I created this caddy." , She developed the CALL ... easy reach. The accessory ensures that the call device can ...
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... The University of California, Davis, and Academia Sinica, ... China (Taiwan), have entered into a collaborative agreement ... program that couples cutting-edge research with opportunities to ... new companies. , The agreement was signed Sept.12 ... research at UC Davis and President Chi-Huey Wong ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2
... rehabilitation professionals expect 20-plus percent employment increases through 2016. ... ... September 8, 2008 -- People reach significant milestones through ... the http://www.nraf-rehabnet.org/ [National Rehabilitation Awareness Foundation], which ...
... Common painkillers like aspirin and ibuprofen appear to lower a ... to help gauge whether a man is at risk of ... appears online Sept. 8 in the journal Cancer , ... to prevent prostate cancer just yet. , "We showed ...
... Pa., Sept. 5 Lieutenant Governor,Catherine Baker Knoll today ... Blood Donor Day., The Commonwealth of Pennsylvania and ... to give blood in commemoration of those who lost ... supplies. One blood,donation can save up to three lives., ...
... John McCain to commit to develop a National AIDS,Strategy ... Sep. 5 The,Republican National Convention concluded last night ... United States and only passing reference to,the epidemic overseas. ... Gov. Sarah Palin mentioned AIDS in their remarks,to Convention ...
... 5 On Saturday, September 6, PARI,Respiratory Equipment will ... part of their "Breathe Easier" series. PARI is highlighted ... as COPD,sufferers, with effective nebulizers and compressors that deliver ... to improve the lives of those affected by respiratory,diseases ...
... disease resistance to anti-hormonal therapy , , FRIDAY, Sept. ... help "re-sensitize" certain breast cancer tumors to anti-hormonal ... , Women with estrogen-receptor or progesterone-receptor positive (ER ... anti-hormonal medicines, such as aromatase inhibitors, to keep ...
Cached Medicine News:Health News:U.S. Demand for Rehabilitation Professionals Grows 2Health News:U.S. Demand for Rehabilitation Professionals Grows 3Health News:Common painkillers lower levels of prostate cancer biomarker 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: